Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Amazon Secures 200 MW Wind Power Deals in Sweden 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Shein Shares Slide 9% in Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
OpenAI Rejects Apple Trade Secret Theft Claims 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Add as a preferred source on Google
SAN DIEGO, March 21, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present a corporate update at the 17th Annual Needham Healthcare Conference at 2:30 pm EDT on Wednesday, March 28, 2018, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Patricia Bitar | Andrew McDonald |
| Chief Financial Officer | LifeSci Advisors LLC |
| (858) 550‐0780 ext. 223 | 646-597-6987 |
| [email protected] | [email protected] |
